New hope for ovarian cancer: Rina-S faces off against chemo in major trial

NCT ID NCT07564141

Recruiting now Disease control Sponsor: Genmab Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 06, 2026 · Updated 7 times

Summary

This large Phase 3 trial will test a new drug called Rina-S, alone or with bevacizumab, against standard platinum-based chemotherapy for women with ovarian cancer that has returned after initial treatment. About 688 participants will be randomly assigned to receive either the new drug or standard chemo. The main goal is to see if Rina-S can delay cancer growth better than current treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rina-S (rinatabart sesutecan) with or without bevacizumab
What this could lead to: If successful, this could offer a new treatment option for women with recurrent platinum-sensitive ovarian cancer, potentially improving how long the cancer stays under control.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The new drug may not work better than standard chemotherapy, and side effects could be similar or different.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer malignant ovarian serous tumor ovarian cancer ovarian carcinoma ovarian endometrioid adenocarcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER PLATINUM-SENSITIVE OVARIAN CANCER

Contacts and locations

Locations

Danbury Hospital
RECRUITING

Danbury, Connecticut, 06810, United States
ProHealth Care Inc
RECRUITING

Waukesha, Wisconsin, 53188, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.